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Uveal	 melanoma	 is	 the	 most	 common	 intraocular	 malignancy	 in	 adults.	 The	 lack	 of	 an	 effective	
treatment	results	in	a	median	survival	time	less	than	one	year	for	patients	with	metastatic	disease.	
Recently,	 our	 lab	 identified	 the	melanoma-specific	 long	non-coding	RNA	 (lncRNA)	SAMMSON	 as	 a	
novel	therapeutic	target	in	skin	melanoma.	
Analysis	of	 a	PAN	cancer	RNA-sequencing	dataset	 revealed	 consistent	 expression	of	SAMMSON	 in	
uveal	 melanoma	 tumors.	 Although	 SAMMSON	 expression	 was	 lower	 in	 uveal	 compared	 to	 skin	
melanoma,	over	90%	of	uveal	melanoma	tumors	showed	detectable	SAMMSON	expression.	Further	
analysis	 also	 revealed	 SAMMSON	 expression	 in	 conjunctival	 melanoma,	 another	 form	 of	 ocular	
melanoma.	To	evaluate	the	therapeutic	potential	of	SAMMSON	 inhibition	in	uveal	and	conjunctival	
melanoma,	 we	 treated	 a	 panel	 of	 representative	 cell	 lines	 with	 SAMMSON-specific	 antisense	
oligonucleotides	(ASOs)	and	observed	a	strong	reduction	in	cell	viability,	accompanied	by	induction	
of	apoptosis.	These	effects	were	dependent	on	ASO	dosing	and	were	validated	using	8	independent	
SAMMSON-targeting	ASOs	and	various	ASO	chemistries.	ASO-treatment	of	a	uveal	melanoma	PDX	
model	 further	 confirmed	 the	 observed	 phenotype.	 In	 line	 with	 the	 function	 of	 SAMMSON	 in	
modulating	 mitochondrial	 metabolism,	 SAMMSON	 knock	 down	 resulted	 in	 a	 decreased	
mitochondrial	 oxidative	 phosphorylation.	 Together,	 our	 results	 demonstrate	 the	 efficacy	 of	
SAMMSON	inhibition	as	a	novel	treatment	option	for	uveal	melanoma	patients.	
	
	
	
	
